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Abstract: Prader-Willi syndrome (PWS) is a complex neurodevelopmental disorder due to errors in genomic imprinting 
with loss of imprinted genes that are paternally expressed from the chromosome 15q11-q13 region. Approximately 70% 
of individuals with PWS have a de novo deletion of the paternally derived 15q11-q13 region in which there are two 
subtypes (i.e., larger Type I or smaller Type II), maternal disomy 15 (both 15s from the mother) in about 25% of cases, 
and the remaining subjects have either defects in the imprinting center controlling the activity of imprinted genes or due to 
other chromosome 15 rearrangements. PWS is characterized by a particular facial appearance, infantile hypotonia, a poor 
suck and feeding difficulties, hypogonadism and hypogenitalism in both sexes, short stature and small hands and feet due 
to growth hormone deficiency, mild learning and behavioral problems (e.g., skin picking, temper tantrums) and 
hyperphagia leading to early childhood obesity. Obesity is a significant health problem, if uncontrolled. PWS is 
considered the most common known genetic cause of morbid obesity in children. The chromosome 15q11-q13 region 
contains approximately 100 genes and transcripts in which about 10 are imprinted and paternally expressed. This region 
can be divided into four groups: 1) a proximal non-imprinted region; 2) a PWS paternal-only expressed region containing 
protein-coding and non-coding genes; 3) an Angelman syndrome region containing maternally expressed genes and 4) a 
distal non-imprinted region. This review summarizes the current understanding of the genetic causes, the natural history 
and clinical presentation of individuals with PWS.  
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INTRODUCTION AND HISTORICAL REVIEW 
 Prader-Willi syndrome (PWS) is a complex 
neurodevelopmental genetic condition due to paternal loss of 
imprinted genes on chromosome 15 and characterized by a 
range of mental and physical findings including obesity that 
can be life-threatening [1, 2]. It affects an estimated 
350,000–400,000 people worldwide. The Prader-Willi 
Syndrome Association (USA) estimates that 17,000–22,000 
individuals live in the United States [3]. Therefore, PWS is 
relatively common with an estimated prevalence worldwide 
in the range of 1 in 10,000 to 30,000 individuals [1, 4]. PWS 
is considered one of the more common disorders seen for 
genetic services and presents in all races and ethnic groups 
[2, 5, 6]. Most cases are sporadic; however, in some families 
a defective control of differentially expressed genes from the 
chromosome 15q11-q13 region is present causing PWS 
through errors in processing of genomic imprints in the PWS 
child and carried by the father. This error can be contributed 
by the father’s mother and lead to recurrence of another child 
with PWS. The risk may be as high as 50% [7, 8]. 
  PWS arises from lack of expression of paternally 
inherited genes known to be imprinted and located in the 
15q11-q13 region. Genomic imprinting is an epigenetic   
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phenomenon whereby the phenotype is modified depending 
on the sex of the parent contributing the gene allele [9] and 
arises from epigenetic changes when expression of genes is 
controlled without changing the DNA sequence. It is 
reversible during gametogenesis. The regulation of gene 
expression is usually through DNA methylation. The control 
of expression of imprinted genes is dependent on the parent 
of origin with mono-allelic gene expression of either the 
maternal or paternal allele for a particular imprinted locus or 
gene.  
  Approximately 70% of individuals with PWS are caused 
by a non-inherited (i.e., de novo) deletion in the paternally 
derived chromosome 15q11-q13 region. The remaining PWS 
individuals (about 25%) result from maternal disomy 15 
(i.e., both chromosome 15s from the mother and no paternal 
chromosome 15), genomic imprinting defects due to 
microdeletions or epimutations of the imprinting center 
located in the 15q11-q13 region in less than 3% of cases, or 
chromosome 15 translocations or rearrangements [1, 2, 6, 7, 
10, 11]. PWS and Angelman syndrome, an entirely different 
clinical disorder involving the same chromosome region, 
were the first examples of errors in genomic imprinting in 
humans [10, 12].  
  The cardinal features of PWS include infantile hypotonia 
and feeding difficulties due to a poor suck, hypogonadism 
and hypogenitalism in both males and females, hyperphagia 
and onset of obesity in early childhood, short stature due to 
growth hormone deficiency, small hands and feet, mild Genetics of Prader-Willi Syndrome  Current Genomics, 2011, Vol. 12, No. 3    205 
intellectual disability (average IQ of 65), behavioral 
problems including skin picking, temper tantrums, 
stubbornness and a particular facial appearance. The facial 
findings include a small upturned nose, narrow bifrontal 
diameter with almond-shaped eyes, down-turned corners of 
the mouth with sticky salivary secretions and generally 
lighter skin, hair and eye color than other family members 
[1, 2, 6, 13-15]. The features of PWS were first documented 
in an adolescent female by J. Langdon Down in 1887 [16], 
but the syndrome went unrecognized until 1956 when 
Prader, Labhart, and Willi reported nine individuals with 
similar clinical findings [17].  
  In 1981, Ledbetter and others [18] used high resolution 
chromosome analysis to show that more than half of the 
individuals with PWS they studied had an interstitial deletion 
of the proximal long arm of chromosome 15 at region q11–
q13. Later, Butler and Palmer [19] studied specific 
polymorphisms found on chromosome 15 and reported that 
the chromosome 15 deletion was de novo in origin and not 
present in either parent. However, in all cases studied the 
deletion was donated from the father. This exclusive paternal 
source of the chromosome deletion was later clarified by 
molecular genetic techniques. Subsequently, a maternal 
deletion of the 15q11-q13 region was reported in a separate 
clinical condition now recognized as Angelman syndrome. 
Butler and others in 1986 [13] reported clinical differences 
in those PWS individuals with and without the chromosome 
15q11-q13 deletion, particularly hypopigmentation and 
greater homogeneity in clinical presentation in those 
individuals with the 15q11-q13 deletion [1, 13, 14].  
  Using Southern hybridization of polymorphic DNA 
markers isolated from the 15q11–q13 region, Nicholls, 
Butler, and others reported in 1989 [10] that individuals with 
PWS and normal-appearing chromosomes inherited both 
chromosome 15s from the mother and none from the father. 
This previously unreported observation was referred to as 
maternal uniparental disomy 15 or maternal UPD 15. Butler 
[14] subsequently characterized the hypopigmentation status 
seen in the majority of individuals with PWS and the 15q 
deletion. We now know that loss of the P (pigment) gene 
located in the 15q11-q13 region leads to hypopigmentation. 
In 2004, Butler and others [20] reported clinical differences 
between individuals with PWS grouped by two types of 
deletions; those with the larger typical 15q11-q13 deletion, 
referred to as Type I, and those with the smaller Type II 
deletion. The individuals with the Type I deletion had more 
behavioral and cognitive problems when compared to those 
with the smaller Type II deletion or maternal disomy 15.  
CLINICAL STAGES AND NATURAL HISTORY 
  The clinical course of PWS has historically been divided 
into two distinct clinical stages (early failure-to-thrive and 
later childhood obesity). With earlier diagnosis and use of 
growth hormone to treat the growth failure, the clinical 
course is becoming more variable. The initial phase of the 
first stage of clinical course development appears unchanged 
and begins in pregnancy. This stage is noted by decreased 
fetal activity. After delivery, central hypotonia and a weak 
cry and suck are present along with a narrow forehead, 
developmental delay, temperature instability, sticky salivary 
secretions, and feeding problems often requiring naso-gastric 
feeding or gastrostomy tube placement. Hypogonadism and 
underdevelopment of the sex organs in both sexes are noted 
during this stage [1, 2, 6, 13, 15, 21].  
  Typically for the non-growth hormone treated child with 
PWS, the second stage of clinical course development begins 
around 2 years of age [13]. This stage is characterized by 
continued developmental delay and onset of hyperphagia 
which leads to obesity if not controlled. Speech articulation 
problems, food foraging, unmotivated sleepiness and 
physical inactivity are common during this time. Other 
features include decreased pain sensitivity, skin picking, 
periods of hypothermia, strabismus, hypopigmentation, 
scoliosis, sleep apnea, and abnormal oral pathology and 
dental anomalies [1-3, 6, 21-23]. PWS children are often 
easy-going and affectionate, but personality problems often 
develop between 3 and 5 years of age, including temper 
tantrums, depression, stubbornness and obsessive 
compulsivity. Sudden outbursts of violence may be observed 
later along with behavioral changes often initiated by 
withholding of food. Poor peer interactions, immaturity, and 
inappropriate social behavior may also occur [6]. These 
patterns continue into adolescence and adulthood (see Fig. 
1). 
Infancy 
  Infants with PWS can sit independently at 1 year of age, 
crawl at 16 months, walk at about 2 years and talk (10 
words) at 39 months [6, 13]. Because of generalized 
hypotonia, neonates with PWS are profoundly floppy. 
However, brain anomalies are not present based on imaging 
studies. Hypotonia and decreased muscle mass can lead to 
respiratory distress and possible asphyxia during illnesses. 
Central adrenal insufficiency has also been reported in PWS 
[24].  
  Most infants with PWS have a weak or absent cry, little 
spontaneous movement, hyporeflexia, excessive sleepiness, 
and poor feeding due to diminished swallowing and sucking 
reflexes which often necessitate gavage feedings and use of 
special nipples lasting for several months. Thus, a major 
focus of treatment is addressing the feeding problems and 
supplying adequate nutrition for growth and development. 
Growth parameters should be regularly assessed (e.g., 
weekly) using recently published growth charts for non-
growth hormone treated infants with PWS [25] during the 
first 6 months of life and then monthly until 2 years of age. 
Calories are adjusted accordingly, but fats should not be 
restricted even though the non-growth hormone treated 
infant with PWS requires less than the recommended 
allowance (often 60% of normal) to avoid rapid weight gain 
once the failure-to-thrive stage has passed. Vitamin and 
mineral intake (e.g., calcium) should be monitored by a 
dietition and supplements given during infancy. Early 
stimulation programs are also recommended, including 
occupational and physical therapies. The use of growth 
hormone is known to alter the clinical presentation [6, 15]. 
Childhood 
  By 18 months of age the feeding pattern in PWS can 
change radically with an insatiable appetite leading to onset 206    Current Genomics, 2011, Vol. 12, No. 3  Merlin G. Butler 
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Fig. (1). (A). Frontal and profile views of a 16 month old female with Prader-Willi syndrome due to maternal disomy 15 and not treated with 
growth hormone. Note the typical facial features of a narrow forehead, short-upturned nose and downturned corners of the mouth. The 
gastrostomy site is noted along with central obesity. 
(B). Facial, profile and hand views of an 18 year old female with Prader-Willi syndrome due to the typical 15q11-q13 deletion and not treated 
with growth hormone. Note the almond-shaped eyes, a narrow forehead, thin upper lip, hypopigmentation, central obesity and small hands. 
of early childhood obesity. Hyperphagia is a major 
behavioral problem in PWS and typically lasts over the 
lifetime. No known pharmacological agent has been 
effective to treat hyperphagia once it develops.  
  Global developmental delays and behavior patterns such 
as temper tantrums, difficulty in changing routines, 
stubbornness, manipulative behavior, and obsessive-
compulsions may become more apparent during childhood. 
Lying, stealing, and aggressive behavior are common during 
this time. Although children with PWS can be affectionate, 
they can also be less agreeable and less open to the 
introduction of new ideas. Without growth hormone 
treatment, they are generally less physically active than other 
children [6].  
  Endocrine abnormalities such as hypothyroidism, growth 
and sex hormone deficiency and adrenal problems are 
reported in PWS and usually recognized early. Enamel 
hypoplasia and dental caries are frequently seen as well as Genetics of Prader-Willi Syndrome  Current Genomics, 2011, Vol. 12, No. 3    207 
strabismus and myopia with impaired stereoscopic vision; 
the latter is more common in maternal disomy 15 [26]. 
Hypopigmentation also becomes more pronounced. A 
characteristic body habitus or posture is more noticeable 
during early childhood with sloping shoulders, central 
obesity, straight lower leg borders and straight ulnar borders 
to the hands. Many of these features improve with growth 
hormone treatment. Small hands and feet and almond-shaped 
eyes become more apparent during mid-childhood.  
  Academic achievement is usually impaired during the 
first 6 years of life. About one-third of children function in 
the low-normal intellectual range (70–100 IQ) and the 
remaining in the mild-to-moderate range (50–70 IQ). The 
average IQ is 65. There are reported differences in behavior, 
academic achievement, and cognition between those with the 
chromosome 15q deletion versus those with maternal disomy 
[27]. 
  Many children begin school in mainstream settings, but 
the intellectual impairment and potential behavioral 
problems will present difficulties in progressing through 
regular classroom settings. Special education and support 
services are often required. Children with PWS have 
relatively strong reading, visual, spatial, and long-term 
memory skills, but have weaker math, sequential processing, 
and short-term memory skills. Verbal skills may be relative 
strengths, particularly in those children with maternal 
disomy, but speech articulation can be a problem requiring 
speech therapy. A common occurrence in those with the 
typical deletion is an unusual skill of working with jigsaw 
puzzles [6, 28].  
Adolescence and Adulthood 
  Puberty is absent, delayed or incomplete in both males 
and females with PWS and infertility is present in the vast 
majority. Menarche may occur but may not be present until 
30 years of age. Amenorrhea or oligomenorrhea is usually 
present and gonadotropin hormone production is low. 
Adolescents and young adults with PWS usually look 
younger than their chronological age [29]. 
  Hypogonadism and hypogenitalism occur in the vast 
majority of individuals with PWS during adolescence. 
Hypothalamic hypogonadism leads to the abnormal gonadal 
development and function. Testosterone and estrogen levels 
are generally low. Cryptorchidism is present in 80-90% of 
males with a small penis and hypoplastic scrotum. A 
hypoplastic labia majora and minora and a small clitoris are 
seen in most females. Penile size increases modestly in many 
males during the third or fourth decade of life, but testicular 
size remains small. Treatment of the small penis with topical 
or parenteral testosterone has been effective, but 
normalization of genital development is rare. Testes may 
descend spontaneously in males during childhood and 
puberty, but often surgical intervention is required. 
Precocious development of pubic and axillary hair occurs in 
about 20% of individuals in both sexes as a consequence of 
premature adrenarche. Beard and body hair are variable, 
occurring later than normal, but generally sparse. Inadequate 
voice change occurs in most males. Little information is 
known about sexual activity in PWS, although individuals 
with PWS show an interest in affection and establishing 
relationships. In PWS females, breast development is normal 
in about one-half of cases with onset between 9 and 13 years 
of age. Pubic hair is normal in about 40% of females. 
Although very rare, pregnancies in females with PWS have 
occurred; there have been no reported pregnancies produced 
from PWS males [6, 30]. 
  Approximately 90% of individuals with PWS without 
growth hormone treatment will have short stature by 
adulthood. The average untreated adult male is 155 cm (61 
inches) tall and the adult female averages 147 cm (58 inches) 
[6]. Growth standards for untreated males and females with 
PWS have been reported between 2 to 22 years of age [31]. 
Growth pattern analysis shows that the 50th centile for 
height in PWS individuals generally falls below the 5th 
centile for normal individuals by age 12 to 14 years. Height 
velocity often declines relative to normal due to the lack of a 
pubertal growth spurt and growth and sex hormone 
deficiencies. Inverse correlations between Z-scores for linear 
measurements (e.g., height, hand and foot lengths) and age 
indicate a deceleration of linear growth with increasing age 
relative to normal individuals. Short stature is almost always 
present by the second decade of life without growth hormone 
replacement [6, 32-35]. 
  Acromicria (small hands and feet) seen during infancy 
and childhood is more pronounced during adolescence and 
adulthood. Foot length tends to be more affected than hand 
length. Scoliosis may also become more pronounced during 
adolescence and kyphosis may be present by early 
adulthood. Genu valgus positioning at the knees may also 
occur [1].  
  Without intervention, adolescents with PWS may weigh 
250 to 300 pounds by their late teens. Beside obesity related 
complications impacting morbidity and mortality, eating 
related fatalities do occur, including choking on gorged food 
and gastric necrosis and rupture [36]. By late adolescence, 
food stealing and hoarding can be problematic as well as 
consuming discarded or inedible food items (e.g., frozen 
food). This often necessitates locking the refrigerator and 
food cabinets to prevent excessive eating. The eating 
behavior and complications of obesity can reduce the life 
expectancy in PWS and cognitive impairments preclude 
adult independent living arrangements. Behavioral and 
psychiatric problems often require medical treatment and 
behavioral management. Psychosis is evident by young 
adulthood in about 10% of individuals with PWS [37, 38]. 
Caloric diet restriction is lifelong and important to control 
obesity. Based on population studies, the death rate in PWS 
is estimated at 3% per year [39].  
  The decreased muscle tone and mass in PWS contributes 
to a lower metabolic rate and physical inactivity with 
subsequent obesity in adolescents and adults. Improvement 
is seen with growth hormone therapy. Sleep disorders and 
respiratory dysfunction in PWS such as hypoventilation and 
oxygen desaturation are also common from childhood to 
adulthood and need to be closely monitored before growth 
hormone treatment. Adolescents have a tendency to fall 
asleep during the day, particularly when they are inactive, 
and they do not sleep soundly at night.  
  Weight and behavior control problems are characteristic 
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members and care providers to address the issues. 
Interventions to control food consumption include locking 
refrigerators, limiting the amount of food at home, continual 
supervision during times of food-related events and 
providing non-food-related rewards. Strict mealtime regimes 
are important. Individually tailored exercise programs are 
also encouraged and should be monitored to reduce weight. 
Adequate protein during times of caloric restriction should 
be encouraged to help conserve lean body mass and is 
particularly needed when growth hormone is prescribed to 
increase stature and muscle mass. Restricted caloric intake 
with vitamin and calcium supplementation is generally 
required by age 2 years and beyond to minimize excessive 
weight gain and prevent osteoporosis [40].  
  Historically, weight maintenance in non-growth hormone 
treated children with PWS requires caloric intake of 8-11 
kcal per cm of height per day (by contrast, children without 
PWS require 11-14 kcal per cm per day for adequate growth) 
[41]. Weight loss has been documented in children by 
restricting their caloric intake to 7 kcal per cm per day. 
Similar guidelines have not yet been developed specifically 
for adolescents and adults with PWS. Hence, a lifetime 
commitment and close observation are required by all 
involved in the care of individuals with PWS, regardless of 
their age or living arrangement. The obesity associated with 
PWS results from a chronic imbalance between energy 
intake and expenditure due to hyperphagia, decreased 
physical activity, reduced metabolic rate and an inability to 
vomit. Individuals with PWS have a lower lean body mass 
compared with controls contributing to reduced energy 
expenditure. Studies have been conducted to determine the 
relationship among body composition, activity levels and 
metabolic rates in PWS. Butler and colleagues [42] 
demonstrated that individuals with PWS had reduced total 
energy expenditure and a lower lean body mass compared 
with obese subjects. In addition, resting energy expenditure 
was significantly reduced by 16% in the individuals with 
PWS compared with control subjects.  
  Theodoro and colleagues [43] studied body composition 
in PWS individuals between 10 to 49 years. Regional fat and 
lean mass patterns were characterized and significant 
differences were found between PWS and obese subjects for 
lean measures of the arms, legs, and trunk. Total lean mass 
was significantly lower in PWS than in obese subjects for 
arms, trunk, and legs, demonstrating an unusual body 
composition and fatness patterns in PWS characterized by 
reduced lean tissue and increased adiposity.  
  Because hyperphagia is the most striking behavior in 
PWS, Holsen and colleagues [44] used functional magnetic 
resonance imaging (fMRI) to study the brain’s response to 
food stimulation images before and after eating in 
individuals with and without PWS. When viewing food and 
non-food images before and after eating, the fMRI scans 
showed that PWS subjects exhibited greater brain activation 
to food pictures in the post-meal state compared to controls. 
The activated brain areas included the orbitofrontal cortex, 
medial prefrontal cortex, insula, hippocampus, and 
parahippocampal gyrus; several of these regions function to 
drive eating behavior. 
  Behavioral and learning problems become more 
prominent during the teenage years, particularly temper 
tantrums, self-injury and obsessions. Typical adolescent 
rebelliousness is often exaggerated, particularly over access 
to food. Self-injurious behavior is reported in 60% of PWS 
adolescents and 81% of adults, with skin picking being the 
most common [45, 46]. Compulsive symptoms have been 
reported in about 60% of individuals with PWS [47] and 
occasionally these behaviors worsen during adulthood. In 
addition, acute psychosis can be seen in about 10% of young 
adults with PWS, particularly in those with maternal disomy.  
  Psychotropic agents can be helpful in controlling 
abnormal behavior, but no specific medication has been 
universally effective in controlling abnormal behavior or 
food-seeking behavior. Serotonin agonists have been used to 
reduce behavioral problems, including temper tantrums and 
compulsions. However, children and adults with PWS are 
typically affectionate and outgoing and show a willingness to 
please others and seek positive attention. When an adult with 
PWS is surrounded by trained and experienced caregivers, 
behaviors can be managed.  
  Adults with PWS have life-oriented goals similar to 
others entering adulthood, including vocation, independent 
living and long term relationships. For most persons with 
PWS, formal education ends between ages 18 and 21. 
However, a gap often exists between completion of school 
and entrance into a job-training program. Challenges may be 
numerous for the adult with PWS and the family members or 
caregivers. In view of potential health problems such as 
behavior and hyperphagia, an appropriate environment 
requires supervised living arrangements with food 
restrictions. Professional sources knowledgeable about PWS 
are required for development of training and sheltered 
employment and housing. Decisions regarding living 
arrangements and availability of food are usually made 
unwisely by persons with PWS; therefore it is optimal to 
have legal guardianship assigned to a parent or other adult. 
PRADER-WILLI SYNDROME: GENETICS 
  Prader-Willi syndrome is a genomic imprinting disorder 
due to an epigenetic phenomenon that evolved about 150 
million years ago and involves modification of the 
phenotype of an individual depending on the parent of origin 
[48]. About 1% of mammalian genes are imprinted and 
frequently affect growth, development and viability. PWS 
and other obesity-related and overgrowth disorders such as 
Albright hereditary osteodystrophy and Beckwith-
Weidemann syndrome are examples of errors in genomic 
imprinting [48].  
  Epigenetics refers to heritable but reversible regulation of 
various genetic functions, including gene expression, which 
is influenced by environmental factors. Nearly all imprinted 
genes have a CpG-rich differentially methylated region 
which usually relates to allele repression. Methylation of 
cytokine bases occurring in the CpG dinucleotides involve 
key regulatory elements of the genes. Defects in the 
imprinting center controlling the activity of imprinted genes 
originate from either parent and can lead to different clinical 
syndromes. For example, the loss of paternally expressed 
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maternal contribution of this chromosome region normally 
silenced by epigenetic factors (e.g., DNA methylation). The 
sister genomic imprinting syndrome, Angelman syndrome, is 
due to loss of maternal expression of genes in the same 
region that are normally silenced on the paternal 
chromosome 15. An ideogram of chromosome 15 and order 
of genes in the 15q11-q13 region is shown in Fig. (2). 
 The  chromosome  15q11-q13  region contains about 8 
million DNA base pairs including a large cluster of 
imprinted genes and also a non-imprinted domain in which 
genes are expressed equally on either the maternal or 
paternal chromosome 15, but with a few genes showing a 
paternal expression bias [11, 49, 50]. Novel low copy repeat 
DNA sequences are clustered at or near the two major 
proximal chromosome breakpoints (BP1 and BP2) and the 
distal breakpoint (BP3) in the 15q11-q13 region [51-53]. The 
typical PWS deletion consists of two classes, Type I and 
Type II. The larger Type I (TI) deletion involves breakpoint 
1 (BP1) which is nearest the centromere while the smaller 
Type II (TII) deletion involves breakpoint 2 (BP2). 
Breakpoint 3 (BP3) is located distally in the 15q11-q13 
region and is common in both typical deletion subgroups 
(see Fig. 2). Butler and colleagues [50] reported that Type I 
deletions were approximately 6.6 Mb in size and the Type II 
deletion was 5.3 Mb. There are four recognized genes 
located between BP1 and BP2 (i.e., GCP5, CYFIP1, NIPA1, 
NIPA2) and individuals were reported recently with 
behavioral and autistic findings with a deletion involving 
only the region between BP1 and BP2 [54]. PWS individuals 
with the larger typical Type I deletion (involving BP1 and 
BP3) appear to have more behavioral problems such as 
obsessive compulsion and self-injury along with lower 
scores on measures of academic performance than seen in 
those PWS individuals with the smaller Type II deletion 
(involving BP2 and BP3) [20]. Atypical deletions involving 
the 15q11-q13 region that are greater or smaller in size than 
the typical Type I or Type II deletions have been reported in 
about 5% of PWS individuals [55]. 
  There are about 100 genes or transcripts identified in the 
15q11-q13 region between BP1 and BP3 and about 10 of 
these genes are imprinted and paternally expressed [2]. DNA 
testing to measure the methylation status of genes in the 
region is quite accurate for diagnosis in about 99% of 
individuals with PWS. However, this testing will not identify 
the specific genetic subtype (deletion, maternal disomy or an 
imprinting defect). Additional testing would be required to 
determine the genetic subtype, including fluorescence in situ 
hybridization (FISH), genotyping with informative DNA 
markers, MLPA testing or chromosomal microarray studies 
[6, 55] (see Figs. 3 and 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Ideogram of chromosome 15 showing the order of protein-coding and non-coding genes and transcripts in the 15q11-q13 region and 
location of breakpoints for the typical Type I and Type II deletions. Abbreviations: Cen, centromere; Tel, telomere; BP, breakpoint; IC, 
imprinting center; snoRNAs, small nucleolar RNAs. 210    Current Genomics, 2011, Vol. 12, No. 3  Merlin G. Butler 
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Fig. (3). Scatterplot of mean normalized values with standard deviations for probes evaluated by multiplex ligation-dependent probe 
amplification (MLPA) with methylation-specific analysis. (A) Gene copy number of a control individual without any deletion or duplication 
of probes in the 15q11-q13 region or elsewhere deleted (average copy number of 2.0 for each probe). (B) Gene copy number of an individual 
with Prader-Willi syndrome and the typical Type I deletion of the 15q11-q13 region extending from GCP5 to OCA2 with other genes on 
chromosome 15 (e.g., APBA2) or other chromosomes not deleted (copy number of 1.0 = deletion; copy number of 2.0 = non-deletion). (C) 
Gene copy number of an individual with Prader-Willi syndrome and the typical Type II deletion of the 15q11-q13 region extending from 
MKRN3 to OCA2 with other genes on chromosome 15 (e.g., APBA2) or other chromosomes not deleted (copy number of 1.0 = deletion; copy 
number of 2.0 = non-deletion).  
  The 15q11-q13 region can be divided into four regions; 
(1) a proximal non-imprinted region between BP1 and BP2 
containing the four biparentally expressed genes; (2) a ‘PWS 
paternal-only expressed region' containing five well 
characterized protein coding genes (MKRN3, MAGEL2, 
NDN, and the bicistronic SNURF-SNRPN), a cluster of five 
snoRNA genes (HBII-436, HBII-13, HBII-438, HBII-85 and 
HBII-52) and several antisense transcripts including the 
antisense transcript to UBE3A; (3) an ‘AS region' containing 
the preferentially maternally expressed genes UBE3A and 
ATP10A and (4) a distal non-imprinted region containing a 
cluster of three GABA receptor genes, the P gene for 
oculocutaneous albinism type 2 (OCA2) and the HERC2 
gene [2, 11].  
 SNRPN  (small nuclear ribonucleoprotein N) and a second 
protein coding sequence (SNURF, or SNRPN u pstream 
reading frame) as well as multiple copies of C/D box small 
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Fig. (4). (A) Using MLPA and methylation specific probes for imprinted genes from the 15q11-q13 region, the percent of methylation can be 
measured to determine a normal or abnormal (Prader-Willi syndrome) methylation pattern. If the percentage of methylation for each 
methylation specific probe (in bold and noted by arrows) falls between 80 to 100 percent, then the diagnosis of Prader-Willi syndrome is 
made but the methylation pattern will not determine the genetic status (i.e., deletion, maternal disomy or imprinting defect). (B) If the 
percentage of methylation for each methylation specific probe (in bold and noted by arrows) falls between 40 to 60 percent, then the diagnosis 
is normal (not Prader-Willi syndrome).  
processing and encoded within the SNURF-SNRPN 
transcript are located in the 15q11-q13 region [56]. Other 
snoRNAs included in this region are SNORD64, SNORD107, 
SNORD109A, SNORD115 and SNORD116 previously 
referred to as HBII-13, HBII-436, HBII-438, HBII-52 and 
HBII-85. The MKRN3, MAGEL2, NDN and C15orf2 genes 
are involved in brain development and function. Exons 4-10 
of the complex bicistronic SNURF–SNRPN gene encodes for 
a core spliceosomal protein (SmN) involved in mRNA 
splicing in the brain, whereas exons 1–3 encode a 71-amino-
acid protein enriched in arginine residues [2, 11, 57]. Necdin 
(NDN) is a paternally expressed gene involved with axonal 
outgrowth and is overly expressed in the hypothalamus, 
thalamus and pons. Mice deficient for the necdin gene show 
delayed migration of the sympathetic neurons, neonatal 
lethality and respiratory problems. The MAGEL2 gene is 
paternally expressed in various brain regions including the 
hypothalamus and appears to play a role in circadian rhythm, 
brain structure, behavior, and fertility in humans. The 
MKRN3 gene is a member of the makorin (MKRN) RING 
finger protein gene family which encodes specific proteins 
(makorins) and abundantly expressed in the central nervous 
system. Two additional genes (PWRN1 and PWRN2) were 
recently identified and located close to the NDN gene. 
PWRN1 appears as a novel alternative start site for SNURF-
SNRPN  while  PWRN2 is male germ cell-specific and 
expressed from the haploid genome [9, 11, 57-59].  
  The two imprinted genes (UBE3A, ATP10C) are 
maternally expressed or paternally silenced and located in 
this chromosome region. The UBE3A gene causes Angelman 
syndrome. Other genes located in the distal area of the 
15q11-q13 region include several gamma aminobutyric acid 
(GABA) receptor subunits called GABRB3, GABRA5, 
GABRG3 which appear to be paternally biased with loss of 
the paternal allele resulting in a reduction of expression of 
greater than 50% [60].
  GABA is a major inhibitory 
neurotransmitter and alterations associated with hunger, 
obsessive-compulsions and abnormal visual perception and 
memory; all present in PWS [26]. The P gene for pigment 
production is also located in the distal end of this 
chromosome region and deleted in both PWS and AS 
individuals. Mutations of this gene cause albinism. 
GENE/TRANSCRIPT EXPRESSION IN PRADER-
WILLI AND ANGELMAN SYNDROMES 
  To further characterize the genetic findings and identify 
unique expression patterns in PWS and AS, custom-made 
cDNA and whole genome-wide expression microarrays were 
used with RNA isolated from lymphoblastoid cell lines 
established from three comparison males and seven PWS 
males with the 15q11-q13 deletion and maternal disomy 15 
[61]. More than 47,000 probes were examined and 23,383 
were detectable. As expected, imprinted genes from the 
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expression. In addition, there was no difference in expression 
levels for biallelically expressed genes (e.g., OCA2) within 
the 15q11-q13 region when comparing maternal disomy 15 
cell lines with controls. However, two genes previously 
identified as maternally expressed (UBE3A,  ATP10C) 
showed a significant increase in expression level in maternal 
disomy cell lines compared with control or PWS deletion 
subjects. Several genes/transcripts (e.g., GABRA5, GABRB3) 
showed increased expression in the PWS maternal disomy 
cells compared with PWS deletion cells, but less than in 
control cells, indicating a paternal bias of expression [60]. 
  Significant differences ( 1.5 fold change with false 
discovery rate of 20%) were found when placed in functional 
categories for 323 genes with expression in lymphoblastoid 
cells from males with PWS relative to comparison males 
characterized with the Ingenuity Pathway Analysis computer 
software program. These categories included the nervous 
system development and function, tissue morphology, 
hematological system development and function and 
regulation of gene expression [61]. Genes showing 
significant changes in expression in the PWS males other 
than those genes known to be imprinted and paternally 
expressed included HCRT [hypocretin (orexin)], POMC 
(pro-opiomelanocortin,  OXTR (oxytocin receptor), MC2R 
(melanocortin receptor) and serotonin receptors 3A, 1B and 
2B; all are involved with eating behavior in humans. Other 
genes of interest with reduced expression in PWS individuals 
included  STAR (a key regulator of steroid synthesis) and 
SAG (an arrestin family member which desensitizes G-
protein-coupled receptors). The impact of the 15q11-q13 
genes involved with coding or non-coding protein 
production on the function of genes located elsewhere in the 
genome and their role in the causation of PWS will require 
further investigations. 
ATYPICAL DELETIONS IN PRADER-WILLI 
SYNDROME: CLINICAL FINDINGS 
  In 1995, Butler and coworkers [62] reported on a 5-year-
old white girl with features of PWS identified during 
infancy. She was found to have a submicroscopic deletion of 
the 15q11-q13 region using FISH and DNA marker analysis. 
The deletion was approximately 100-200 kb in size and 
showed a de novo paternal deletion of the imprinting center 
and the SNRPN gene region including SNORD116. She 
developed a milder PWS phenotype with decreased growth, 
cognitive and behavioral problems than typically seen in 
PWS. She also had normal pigmentation. 
  More recently, a female patient with an atypical deletion 
of the chromosome 15q11-q13 region was reported due to an 
unbalanced chromosome 15 translocation involving only a 
paternal deletion of the MKRN3, MAGEL2 and NDN genes 
[63]. She presented with obesity, mental retardation and a 
high pain threshold but lacked other features of PWS. Other 
patients included a male child with several features of PWS 
reported by Sahoo and colleagues in 2008 [64]. The features 
included neonatal hypotonia, feeding problems, obesity, and 
hypogenitalism, but with increased birth weight, a large head 
and facial appearance not consistent with PWS. Genetic 
testing showed a paternal deletion of snoRNA SNORD116 
and part of the SNORD115 gene cluster. Smith and 
colleagues [65] reported a 19-year-old male with 
hyperphagia and severe obesity, mild intellectual disability 
and hypogonadism with a 187 kb deletion which included 
SNORD116. Deletions involving the proximal long arm of 
chromosome 15 can be smaller or larger than the typical 
deletion in individuals with features of PWS as supported by 
a recent report by Butler and colleagues [66] of an infant girl 
with a de novo interstitial 15q11-q14 deletion, which is 
larger than the typical deletion. She presented with 
hypotonia, a poor suck, feeding problems, mild 
micrognathia, preauricular ear tags, a high arched palate, 
edematous feet and coarctation of the aorta; several of these 
features are not typical for PWS but reported previously in 
individuals with this expanded deletion of chromosome 15.  
  Clinical reports of atypical deletions (larger and smaller) 
give further insight into the genes causing PWS. The very 
small atypical deletions appear to contribute to several PWS 
features, specifically the paternally expressed snoRNAs 
including  SNORD115 and SNORD116. In addition, mice 
with the snoRNA equivalent of SNORD116 removed causes 
hyperphagia and growth deficiency. Furthermore, Kishore 
and Stamm [67] reported that the paternally expressed 
snoRNA  SNORD115 regulates alternative splicing of the 
serotonin 5-HT2C receptor leading to an abnormal receptor 
involved with eating behavior. Therefore, PWS appears not 
to be caused by a single locus or gene defect, but by a 
deficiency of a combination of imprinted genes in the 15q11-
q13 region including SNURF-SNRPN and the SNORD genes 
[64]. Deficiencies of other imprinted genes in the region, 
including MKRN3, MAGEL2 and/or NDN apparently play a 
role but not sufficient alone to generate the cardinal features 
recognized in Prader-Willi syndrome.  
CLINICAL COMPARISON OF GENETIC SUBTYPES 
IN PRADER-WILLI SYNDROME 
  Individuals with PWS who have the typical chromosome 
15 deletion are hypopigmented and more homogeneous in 
their clinical presentation [1, 13]. Those with maternal 
disomy have fewer typical facial features and are less likely 
to have certain behavioral findings such a skin picking, 
unusual skill with jigsaw puzzles, a high pain threshold and 
articulation problems. PWS individuals with maternal 
disomy are usually diagnosed later, which may reflect a 
milder phenotype. PWS individuals with the 15q11-q13 
deletion have a greater number of compulsive symptoms 
than those with maternal disomy 15 [47, 68]. Furthermore, 
PWS children with the deletion possess relative strengths in 
standardized visual-spatial tasks such as object assembly 
[28].  
  Measures of intellectual function and academic 
achievement in PWS have shown that those with maternal 
disomy have significantly higher verbal IQ scores than those 
with the typical deletion [27]. However, PWS deletion 
individuals score higher on object-assembly subtests, 
supporting specific visual perceptual skills as relative 
strengths in these individuals. Discrimination of shape and 
motion testing and kinetic form visual performance in the 
maternal disomy group are generally worse than seen in the 
deletion individuals. However, the superior visual 
recognition memory is greater in the maternal disomy 
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  To further characterize clinical differences in the genetic 
subtypes in PWS, Butler and colleagues [20] reported 
differences in psychological, cognitive and behavioral data 
collected from young adults with PWS representing the 
longer Type I deletion involving breakpoints BP1 and BP3 
versus those with the shorter Type II deletion involving BP2 
and BP3. PWS individuals with Type I deletions scored 
significantly worse in self-injurious and maladaptive 
behavior assessments compared with Type II deletions. 
Obsessive–compulsive behavior was also more common in 
Type I deletions. Adaptive behavior scores were generally 
more abnormal including lower reading and math skills and 
more compulsions in Type I versus Type II deletion 
individuals. Intellectual ability and academic achievement 
were lower in individuals with Type I deletion (see Table 1).  
  To help explain the genetic deletion subtype differences, 
Bittel and colleagues [69] studied expression patterns of four 
genes (GCP5, CYFIP1, NIPA2, NIPA1) located between 
BP1 and BP2 and correlated the expression with behavioral, 
maladaptive and intellectual ability scores in the two PWS 
deletion groups. Three of these genes are implicated in 
central nervous system development. Correlation studies 
with gene expression and behavioral and cognitive scores 
indicated a direct relationship between the quantity of gene 
message and higher assessment scores. The coefficient of 
determination indicated the quantity of messenger RNA of 
the four genes explained 24% to 99% of the variation of the 
behavioral and academic assessment scores, with NIPA2 
having the greatest impact.  
  In summary, strides are being made to better understand 
the role of genetics and impact on clinical care in PWS and 
other genetic conditions. The publication of Health 
Supervision for Children with Prader-Willi syndrome 
published in Pediatrics [70] and the use of interactive 
computer websites such as the Prader-Willi Syndrome 
Diagnosis Module in the Medical Home Portal (www. 
med.calhomeportal.org) can provide useful information to 
care providers treating individuals with PWS. Other internet 
sites include the Prader-Willi Syndrome Association (USA) 
at www. pwsausa.org; Foundation for Prader-Willi Research 
at www.fpwr.org; Foundation for Prader-Willi Research 
Canada at www.onesmarcstep.ca and the International 
Prader-Willi Syndrome Organization at www.ipwso.org. 
These are excellent online sources of information for the 
parents and health care providers needed for management 
and care of individuals at all ages with Prader-Willi 
syndrome.  
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PWS  =  Prader-Willi syndrome  
AS  =  Angelman syndrome  
DNA  =  Deoxyribonucleic acid  
IQ  =  Intelligence quotient  
UPD  =  Uniparental disomy  
fMRI  =  Functional magnetic resonance imaging  
MLPA  =  Multiplex ligation-dependent probe amplification 
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